https://scholars.lib.ntu.edu.tw/handle/123456789/629198
標題: | Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study | 作者: | Kuo, Feng-Yu Lee, Cheng-Han Lan, Wei-Ren Su, Cheng-Huang Lee, Wen-Lieng YI-CHIH WANG Lin, Wei-Shiang Chu, Pao-Hsien Lu, Tse-Min Lo, Ping-Han Tsukiyama, Shuji Yang, Wei-Chen Cheng, Li-Chung Huang, Chien-Lung Yin, Wei-Hsian Liu, Ping-Yen |
關鍵字: | Acute coronary syndrome; CYP2C19; Clopidogrel; Percutaneous coronary intervention; Prasugrel | 公開日期: | 九月-2022 | 出版社: | ELSEVIER TAIWAN | 卷: | 121 | 期: | 9 | 起(迄)頁: | 1786 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Pharmacogenetics is a potential driver of the "East Asian paradox," in which East Asian acute coronary syndrome (ACS) patients receiving dual antiplatelet therapy (DAPT) with clopidogrel following percutaneous coronary intervention (PCI) demonstrate higher levels of platelet reactivity on treatment than Western patients, yet have lower ischemic risk and higher bleeding risk at comparable doses. However, the impact of pharmacogenetics, particularly regarding CYP2C19 genotype, on the pharmacodynamics of P2Y12 inhibitors has not been extensively studied in Taiwanese ACS patients as yet. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/629198 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2022.01.013 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。